SOURCE: Oryzon Genomics

Oryzon Genomics

March 02, 2015 08:30 ET

Dr. Carlos Buesa, Oryzon Genomics CEO, to Be a Keynote Speaker at the 15th Annual Global Discovery-Summit 2015 in Lisbon, Portugal

To Highlight Oryzon's Progress in Epigenetic Approaches for the Treatment of Alzheimer's Disease

BARCELONA, SPAIN and CAMBRIDGE, MA--(Marketwired - Mar 2, 2015) - Oryzon Genomics, a private clinical stage biopharmaceutical company focused on epigenetic based therapeutics in oncology and neurodegenerative diseases, today announced that its CEO, Dr. Carlos Buesa will be presenting as a keynote speaker at the 15th Annual Global Discovery-Summit 2015 at Grande Real Villa Italia Hotel in Cascais, Lisbon, Portugal, to be held on March 16-17, 2015. The presentation is titled "Evaluating Epigenetic Approaches for Alzheimer's Disease". The Keynote Presentation is scheduled for 8:00 am CET, Tuesday, March 17, 2015 at the Principe de Saboia I ballroom.

Dr. Buesa will also present Oryzon's progress with its lead neurodegenerative drug development program ORY-2001, the first histone demethylase inhibitor to advance to clinical studies for the treatment of Alzheimer's Disease in 2015.

The Annual Global Discovery Summit is a premium forum bringing the industry's foremost strategists and thought leaders together to deliver visionary keynote presentations, real-life case studies and interactive sessions. The summit offers global R&D and drug discovery professionals an excellent format for a focused discussion of key new drivers shaping discovery research and development.

In this 15th edition, the Global Discovery Summit has one of its main focuses on the challenge of designing new therapies for neurodegenerative disorders with some other keynote presentations on this space given by Dr Gregor Macdonald, Head of Neuroscience Medicinal Chemistry of Johnson & Johnson, and Professor Alan Palmer, CEO of Cerebroscience & Co-founder & Director of MS Therapeutics. Dr Carlos Buesa, CEO of Oryzon will review in his Keynote Presentation "Evaluating Epigenetic Approaches for Alzheimer's Disease", the different approaches taken by the industry on different diseases and will discuss Oryzon's programs centered in Lysine specific demethylase 1 (LSD1, KDM1A), an epigenetic modulator able to regulate gene expression by demethylating histones.

Oryzon Genomics Epigenetics Drug Development
LSD1 forms part of protein complexes involved in transcriptional regulation, and misregulation of these transcriptional complexes may result in disease. Molecules discovered and developed by Oryzon have shown efficacy in the treatment of acute myeloid leukemia (AML). Oryzon's forerunner molecule, ORY-1001, is a potent and selective LSD1 inhibitor, with excellent pharmacological characteristics that reduces leukemic stem cell potential, potently inhibits colony formation, overcomes the differentiation block in AML cell lines, and induces apoptosis in selected AML and solid tumor cell lines. Oryzon entered a global strategic collaboration with ROCHE in April 2014 for its lead clinical program, ORY-1001 a LSD1 inhibitor for the treatment of leukemia and other malignancies, currently in Phase I/IIA. Under the terms of the agreement, Oryzon received an upfront payment and near-term milestones totalling $21 million, plus potential development, commercial and sales milestones that could exceed $500 million, and royalties on net sales.

The potential use of LSD1 inhibitors is not limited to oncological diseases. LSD1 is well known to partner with Co-REST and REST/NRSF, a gene involved in the repression of neuronal genes in non-neuronal cells. Aberrant levels or activity of REST/Co-REST complexes have been implicated in different neurodegenerative diseases like Parkinson's disease, Huntington's disease, Rett syndrome and increased REST expression has been found in the brain of Alzheimer's disease patients. Data in animal models of these neurodegenerative disorders obtained with Oryzon's CNS candidate ORY-2001 and other LSD1 inhibitors will be presented. The company is expecting to move ORY-2001 a dual LSD1-MAOB inhibitor for the treatment of neurodegenerative disorders, into clinical studies later this year.

ABOUT ORYZON
Founded in 2000 in Barcelona, Spain, Oryzon (www.oryzon.com) is a privately held, clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative epigenetic-based therapeutics in oncology and neurodegenerative diseases. Its LSD1 program is currently covered by 18 patent families. The company has a strong technological platform for biomarker identification, and performs biomarker and target validation for a variety of malignant and neurodegenerative diseases. Oryzon's strategy is to develop first in class compounds against novel epigenetic targets through Phase II clinical trials, at which point we decide to either continue development in-house or to pursue strategic collaborations for late stage development and commercialization. In October 2014, Oryzon announced opening of its U.S. operations in Cambridge, Massachusetts through its U.S. affiliate, Oryzon Corp.

Contact Information